Pfizer price target lowered to $33 from $35 at Guggenheim

Guggenheim lowered the firm’s price target on Pfizer (PFE) to $33 from $35 and keeps a Buy rating on the shares. Pfizer will be releasing their initial FY25 guidance on Tuesday, December 17 before the market opens and ahead of that release the firm updated its model after catching up with the investor relations team and reviewing the latest prescription data for key products for the first two months of Q4, the analyst tells investors. The model changes lower its FY24 EPS view to $2.99 from $3.03 and FY25 EPS forecast to $2.88 from $3.22, the analyst noted.